Bildkälla: Stockfoto

Active Biotech Q1 2023: New Results from naptumomab - Redeye

Redeye comments on Active Biotech’s Q1 report. After the end of Q1, results from naptumomab’s phase I/IIa study with durvalumab were published which we discuss.

Redeye comments on Active Biotech’s Q1 report. After the end of Q1, results from naptumomab’s phase I/IIa study with durvalumab were published which we discuss.
Börsvärldens nyhetsbrev
ANNONSER